Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRGX CARGO Therapeutics	$4.19 -0.7%	$4.30	$3.00 ▼ $25.45	$193.20M	0.31	574,974 shs	610,988 shs
GRNA GreenLight Biosciences	$0.30	$0.30	$0.18 ▼ $5.90	$45.43M	1.44	486,986 shs	732 shs
OCGN Ocugen	$0.98 -4.5%	$0.88	$0.52 ▼ $1.98	$287.39M	4.2	4.57 million shs	48.25 million shs
PLX Protalix BioTherapeutics	$1.54 +6.2%	$1.92	$0.82 ▼ $3.10	$122.60M	-0.2	578,598 shs	12.69 million shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRGX CARGO Therapeutics	0.00%	-1.87%	-1.18%	+2.95%	-74.48%
GRNA GreenLight Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%
OCGN Ocugen	0.00%	-7.16%	+16.56%	+38.61%	-36.51%
PLX Protalix BioTherapeutics	0.00%	+10.00%	-0.65%	-39.84%	+31.62%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRGX CARGO Therapeutics	2.5004 of 5 stars	2.9	0.0	0.0	0.0	3.3	1.7	1.3
GRNA GreenLight Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OCGN Ocugen	1.3726 of 5 stars	3.5	1.0	0.0	0.0	2.5	0.0	0.0
PLX Protalix BioTherapeutics	2.4246 of 5 stars	3.5	3.0	0.0	0.0	0.6	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRGX CARGO Therapeutics	1.86	Reduce	$15.00	258.00% Upside
GRNA GreenLight Biosciences	0.00	N/A	N/A	N/A
OCGN Ocugen	3.00	Buy	$6.00	509.69% Upside
PLX Protalix BioTherapeutics	3.00	Buy	$15.00	874.03% Upside

Current Analyst Ratings Breakdown

Latest GRNA, CRGX, OCGN, and PLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	OCGN Ocugen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
6/24/2025	OCGN Ocugen	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
5/12/2025	OCGN Ocugen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $7.00
5/12/2025	OCGN Ocugen	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	$7.83 per share	N/A
GRNA GreenLight Biosciences	$10.20M	4.45	N/A	N/A	$0.32 per share	0.94
OCGN Ocugen	$4.05M	70.96	N/A	N/A	$0.10 per share	9.84
PLX Protalix BioTherapeutics	$59.76M	2.05	$0.09 per share	17.80	$0.47 per share	3.28

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRGX CARGO Therapeutics	-$167.50M	-$4.62	N/A	N/A	N/A	N/A	-45.93%	-39.58%	8/11/2025 (Estimated)
GRNA GreenLight Biosciences	-$167.05M	-$1.14	N/A	∞	N/A	-1,521.00%	-374.26%	-122.78%	N/A
OCGN Ocugen	-$54.05M	-$0.19	N/A	N/A	N/A	-1,271.12%	-223.00%	-92.20%	8/6/2025 (Estimated)
PLX Protalix BioTherapeutics	$8.31M	$0.04	N/A	4.97	N/A	-21.03%	-30.89%	-11.74%	N/A

Latest GRNA, CRGX, OCGN, and PLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/9/2025	Q1 2025	OCGN Ocugen	-$0.06	-$0.05	+$0.01	-$0.05	N/A	$1.48 million
5/9/2025	Q1	PLX Protalix BioTherapeutics	N/A	-$0.05	N/A	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	N/A
GRNA GreenLight Biosciences	N/A	N/A	N/A	N/A	N/A
OCGN Ocugen	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRGX CARGO Therapeutics	N/A	6.30	6.30
GRNA GreenLight Biosciences	0.49	1.21	1.21
OCGN Ocugen	1.74	2.60	2.60
PLX Protalix BioTherapeutics	N/A	1.98	1.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRGX CARGO Therapeutics	93.16%
GRNA GreenLight Biosciences	24.41%
OCGN Ocugen	10.27%
PLX Protalix BioTherapeutics	16.53%

Insider Ownership

Company	Insider Ownership
CRGX CARGO Therapeutics	2.92%
GRNA GreenLight Biosciences	30.30%
OCGN Ocugen	4.29%
PLX Protalix BioTherapeutics	6.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRGX CARGO Therapeutics	116	46.11 million	44.76 million	N/A
GRNA GreenLight Biosciences	280	151.68 million	105.72 million	Not Optionable
OCGN Ocugen	80	292.03 million	279.50 million	Optionable
PLX Protalix BioTherapeutics	200	79.61 million	69.00 million	Optionable

GRNA, CRGX, OCGN, and PLX Headlines

Recent News About These Companies

Financial Review: Protalix BioTherapeutics (NYSE:PLX) versus Calidi Biotherapeutics (NYSE:CLDI)

2 hours ago | americanbankingnews.com

Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

May 14, 2025 | finance.yahoo.com

PLX: First Quarter Results

May 13, 2025 | msn.com

Earnings call transcript: Protalix Q1 2025 results miss forecasts, stock plunges

May 10, 2025 | uk.investing.com

Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2025 Earnings Call Transcript

May 10, 2025 | insidermonkey.com

Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results

May 10, 2025 | finanznachrichten.de

Protalix BioTherapeutics Q1 Earnings Preview

May 10, 2025 | msn.com

1PLX : Uncovering Potential: Protalix BioTherapeutics's Earnings Preview

May 10, 2025 | benzinga.com

Protalix BioTherapeutics, Inc. (PLX) Q1 2025 Earnings Call Transcript

May 9, 2025 | seekingalpha.com

Protalix eyes Phase II gout trial later this year following solid Q1 revenue growth

May 9, 2025 | proactiveinvestors.com

Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results

May 9, 2025 | prnewswire.com

Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025

May 6, 2025 | seekingalpha.com

Why Protalix BioTherapeutics, Inc.’s (PLX) Stock Is Up 8.71%

April 15, 2025 | aaii.comA

Protalix BioTherapeutics Is A Strong Buy With Increasing Revenues And A Promising Pipeline

April 10, 2025 | seekingalpha.com

Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025

March 24, 2025 | finance.yahoo.com

Is Protalix BioTherapeutics (PLX) The High Growth Low Debt Stock to Invest in Now?

March 22, 2025 | msn.com

Protalix Biotherapeutics chairman discusses breakthrough in gout treatment, drug pipeline - ICYMI

March 21, 2025 | proactiveinvestors.com

Protalix Stock (PLX) Grabbing Attention with Record Revenue Surge

March 20, 2025 | markets.businessinsider.com

Protalix BioTherapeutics, Inc. (PLX) Q4 2024 Earnings Call Transcript

March 19, 2025 | seekingalpha.com

Amended: Protalix Annual Earnings Fall

March 19, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRNA, CRGX, OCGN, and PLX Company Descriptions

CARGO Therapeutics NASDAQ:CRGX

$4.19 -0.03 (-0.71%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.26 +0.06 (+1.55%)

As of 04:05 AM Eastern

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

GreenLight Biosciences NASDAQ:GRNA

FUNR manufactures and sells all-natural juice beverages. Its products include pomegranate cranberry, wild berry and passion fruit-orange. The company was founded by Alex C. Procopio on July 22, 1980 and is headquartered in Las Vegas, NV.

Ocugen NASDAQ:OCGN

$0.98 -0.05 (-4.46%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.00 +0.01 (+1.11%)

As of 04:20 AM Eastern

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Protalix BioTherapeutics NYSE:PLX

$1.54 +0.09 (+6.21%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.28 -0.26 (-16.88%)

As of 04:00 AM Eastern

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time